Edoxaban for treatment of venous thromboembolism in patients with cancer Rationale and design of the Hokusai VTE-cancer study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10322984" target="_blank" >RIV/00216208:11130/15:10322984 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10322984

Výsledek na webu

<a href="http://dx.doi.org/10.1160/TH15-06-0452" target="_blank" >http://dx.doi.org/10.1160/TH15-06-0452</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1160/TH15-06-0452" target="_blank" >10.1160/TH15-06-0452</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Edoxaban for treatment of venous thromboembolism in patients with cancer Rationale and design of the Hokusai VTE-cancer study

Popis výsledku v původním jazyce

Direct oral anticoagulants may be effective and safe for treatment of venous thromboembolism (VTE) in cancer patients, but they have not been compared with low-molecular-weight heparin (LMWH), the current recommended treatment for these patients. The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer. We present the rationale and some design features of the study. One such feature is the composite primary outcome of recurrent VTE and major bleeding during a 12-month study period. These two complications occur frequently in cancer patients receiving anticoagulant treatment and have a significant impact. The evaluation beyond six months will fill the current gap in the evidence base for the long-term treatment of these patients. Based on the observation that the risk of recurrent VTE in patients with active cancer is similar to that in those wi

Název v anglickém jazyce

Edoxaban for treatment of venous thromboembolism in patients with cancer Rationale and design of the Hokusai VTE-cancer study

Popis výsledku anglicky

Direct oral anticoagulants may be effective and safe for treatment of venous thromboembolism (VTE) in cancer patients, but they have not been compared with low-molecular-weight heparin (LMWH), the current recommended treatment for these patients. The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer. We present the rationale and some design features of the study. One such feature is the composite primary outcome of recurrent VTE and major bleeding during a 12-month study period. These two complications occur frequently in cancer patients receiving anticoagulant treatment and have a significant impact. The evaluation beyond six months will fill the current gap in the evidence base for the long-term treatment of these patients. Based on the observation that the risk of recurrent VTE in patients with active cancer is similar to that in those wi

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Thrombosis and Haemostasis

ISSN

0340-6245

e-ISSN

—

Svazek periodika

114

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

9

Strana od-do

1268-1276

Kód UT WoS článku

000365769200020

EID výsledku v databázi Scopus

2-s2.0-84951336304